Coya Therapeutics Inc
COYA
Company Profile
Business description
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
Contact
5850 San Felipe Street
Suite 500
HoustonTX77057
USAT: +1 800 587-8170
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
8
Stocks News & Analysis
stocks
Chart of the Week: China demand for copper falls amidst record rally
Elevated copper prices raise valuation questions.
stocks
Reporting season was stronger than share prices suggest
What 164 ASX earnings results revealed.
stocks
How Anthropic makes money—and what investors should know ahead of its IPO filing
Part one of a two-part Q&A with PitchBook senior analyst Harrison Rolfes on Anthropic’s business model and why it needs to grow margins, fast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,198.30 | 37.90 | 0.41% |
| CAC 40 | 8,286.40 | 5.77 | 0.07% |
| DAX 40 | 26,003.32 | 163.99 | 0.63% |
| Dow JONES (US) | 53,693.55 | 631.60 | 1.19% |
| FTSE 100 | 10,831.52 | 75.07 | 0.70% |
| HKSE | 25,213.31 | 97.90 | -0.39% |
| NASDAQ | 26,589.81 | 371.98 | 1.42% |
| Nikkei 225 | 64,214.48 | 111.16 | -0.17% |
| NZX 50 Index | 13,846.18 | 84.39 | -0.61% |
| S&P 500 | 7,747.98 | 81.38 | 1.06% |
| S&P/ASX 200 | 9,020.10 | 46.10 | 0.51% |
| SSE Composite Index | 3,942.09 | 0.70 | 0.02% |